Mercer Global Advisors
ACTU

Mercer Global Advisors’s Actuate Therapeutics ACTU Stock Holding History

Mercer Global Advisors’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,344
Closed -$111K – 2402
2025
Q1 		$111K Hold
16,344
– – ﹤0.01% 2049
2024
Q4 		$130K Buy
+16,344
New +$133K ﹤0.01% 2014

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NU
Northwestern University Evanston, Illinois $63.3M AUM 0.76% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return

Mercer Global Advisors's ACTU Position: Q2 2025 in Review

Mercer Global Advisors sold out of Actuate Therapeutics (ACTU) in Q2 2025, closing a stake of 16,344 shares — an estimated $111K sold.

Mercer Global Advisors first reported a position in ACTU in Q4 2024 and held it in 2 quarters. The position peaked at $130K in Q4 2024. 38 funds tracked by Wall St. Rank hold ACTU as of Q2 2025.

  • Mercer Global Advisors reported no remaining Actuate Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mercer Global Advisors sold 16,344 Actuate Therapeutics shares in Q2 2025, an estimated $111K.
  • Mercer Global Advisors first reported a position in Actuate Therapeutics in Q4 2024 and held it in 2 quarters.
  • Mercer Global Advisors's Actuate Therapeutics position peaked at $130K in Q4 2024.
  • 38 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2025.

Based on Mercer Global Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.